Rosen Quoted on Research Firm Asking FDA to Clear Path for Generic Fosamax

03 July 2014 Law360 News


Partner David Rosen was quoted in a Law360 article published on July 3, 2014, titled “Research Firm Asks FDA to Clear Path for Generic Fosamax.” The article discussed a citizen petition made by the research firm Clinipace Worldwide asking the U.S. Food and Drug Administration to issue a finding that Merck & Co. did not discontinue the osteoporosis drug Fosamax for health and safety reasons. Rosen was quoted saying, “There have been relatively few instances where the FDA has withdrawn the reference listed drug for reasons related to safety or effectiveness.”